Zoetis Inc. (NYSE:ZTS) Shares Acquired by Telos Capital Management Inc.

Telos Capital Management Inc. lifted its stake in Zoetis Inc. (NYSE:ZTS) by 16.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,639 shares of the company’s stock after purchasing an additional 4,899 shares during the period. Telos Capital Management Inc.’s holdings in Zoetis were worth $6,837,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Zoetis during the fourth quarter worth about $745,861,000. Morgan Stanley lifted its stake in Zoetis by 34.6% in the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after buying an additional 2,796,694 shares in the last quarter. Moneta Group Investment Advisors LLC grew its holdings in Zoetis by 124,281.9% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock valued at $341,778,000 after buying an additional 2,330,285 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Zoetis by 171.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock worth $627,335,000 after buying an additional 2,102,306 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in Zoetis during the third quarter worth $176,219,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now owns 15,723 shares in the company, valued at $2,725,267.59. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 2,209 shares of company stock valued at $408,453. Company insiders own 0.15% of the company’s stock.

Zoetis Trading Down 0.7 %

Shares of ZTS stock traded down $1.03 on Wednesday, reaching $151.99. 2,107,534 shares of the stock were exchanged, compared to its average volume of 2,948,981. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The stock has a market cap of $69.51 billion, a P/E ratio of 30.18, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The firm has a 50 day moving average of $178.25 and a two-hundred day moving average of $180.59. Zoetis Inc. has a 1-year low of $148.48 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the prior year, the company earned $1.15 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. On average, research analysts anticipate that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 1.14%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is currently 34.12%.

Analyst Ratings Changes

A number of research firms recently commented on ZTS. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price target on shares of Zoetis in a report on Tuesday, December 19th. The Goldman Sachs Group upped their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus decreased their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Finally, Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $221.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.